Acadia Pharmaceuticals (ACAD) soars 51% after saying that the results of a Phase III trial of...
Acadia Pharmaceuticals (ACAD) soars 51% after saying that the results of a Phase III trial of its Pimavanserin drug, plus other data, are enough for the company to file an application for FDA approval. Acadia will not now conduct a confirmatory phase III trial that was due to start this month. Pimavanserin is designed to treat Parkinson's disease psychosis. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 8:54AM)
at Nasdaq.com (Feb 3, 2015)
at Nasdaq.com (Jan 23, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Dec 12, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs